Fidelity Management & Research Co.. recently announced the acquisition of new stake in Nabriva Therapeutics plc (NASDAQ:NBRV). The institutional investor has increased its shareholding in the Healthcare company by 134.18% to 14.29 million shares with purchase of 8.19 million shares. This fresh investment now brings its stake to 10.00% valued currently at $10.86 million. In addition, Hudson Bay Capital Management LP raised its holdings by 5.45 million to 5.45 million shares. And ACATIS Investment Kapitalverwaltu.. has lifted its position by 0.05% or 756.0 shares – to 1.4 million shares.
With over 1.12 million Nabriva Therapeutics plc (NBRV) shares trading Friday and a closing price of $0.62 on the day, the dollar volume was approximately $0.69 million. The shares have shown a negative weekly performance of -3.13% and its price on 08/28/20 gained nearly 1.64%. Currently, there are 143.82M common shares owned by the public and among those 142.04M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for NBRV have a consensus price objective of $1.75. The analysts have set the share’s price value over the next 12 months at a high of $2.00 and a low of $1.50 should the stock experience a downside. Incidentally, analysts’ outlook for the Nabriva Therapeutics plc stock is 2.80 for the next 12 months. But an upside of 69.0% will see the stock hit the forecast high price target while mean target price for the stock is $1.75.
Insiders at the company have transacted a total of 63 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 18 of these insider trades were purchases, accounting for 1,118,550 shares. Insider sales of the common stock occurred on 45 occasions, with total insider shares sold totaling 60,631 shares.
The top 3 mutual fund holders in Nabriva Therapeutics plc are Fidelity Advisor Series I -Growth, Fidelity VIP III – Growth Opportu, and Acatis Datini Valueflex Fonds. Fidelity Advisor Series I -Growth owns 11.27 million shares of the company’s stock, all valued at over $8.56 million. The company bought an additional 6.81 million shares recently to bring their total holdings to about 7.88% of the shares outstanding. Fidelity VIP III – Growth Opportu bought 1.05 million shares to see its total holdings expand to 1.63 million shares valued at over $1.24 million and representing 1.14% of the shares outstanding. Acatis Datini Valueflex Fonds bought 756.0 shares to bring its total holdings to over 1.4 million shares at a value of $1.06 million. Acatis Datini Valueflex Fonds now owns shares totaling to 0.98% of the shares outstanding.
Shares of Nabriva Therapeutics plc (NASDAQ: NBRV) opened at $0.599, down -$0.01 from a prior closing price of $0.61. However, the script later closed the day at $0.62, up 1.64%. The company’s stock has a 5-day price change of -3.13% and -20.61% over the past three months. NBRV shares are trading -53.03% year to date (YTD), with the 12-month market performance down to -69.76% lower. It has a 12-month low price of $0.49 and touched a high of $2.68 over the same period. Currently, 1.12 million shares have been traded, compared to an average intraday trading volume of 9.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.68%, -14.94%, and -40.31% respectively.
Institutional ownership of Nabriva Therapeutics plc (NASDAQ: NBRV) shares accounts for 32.40% of the company’s 143.82M shares outstanding. Mutual fund holders own 13.22%, while other institutional holders and individual stakeholders account for 8.54% and 12.15% respectively.
It has a market capitalization of $87.70M and a beta (3y monthly) value of 2.24. The earnings-per-share (ttm) stands at -$0.91. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.74% over the week and 5.84% over the month.
Analysts forecast that Nabriva Therapeutics plc (NBRV) will achieve an EPS of -$0.1 for the current quarter, -$0.1 for the next quarter and -$0.41 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.12 while analysts give the company a high EPS estimate of -$0.08. Comparatively, EPS for the current quarter was -$0.24 a year ago. Earnings per share for the fiscal year are expected to increase by 50.60%, and 19.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Nabriva Therapeutics plc (NBRV) as a “Moderate Buy” at a consensus score of 2.80. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 4 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NBRV, a number of firms have released research notes about the stock. Wedbush stated their Neutral rating for the stock in a research note on March 19, 2020, with the firm’s price target at. Gabelli & Co coverage for the Nabriva Therapeutics plc (NBRV) stock in a research note released on May 02, 2019 offered a Hold rating with a price target of. H.C. Wainwright was of a view on May 02, 2019 that the stock is Buy, while Morgan Stanley gave the stock Overweight rating on September 07, 2018, issuing a price target of. BofA/Merrill on their part issued Buy rating on March 21, 2018.